Evidence map›Paper›PMID 32373292›Full record

ArticleIranian journal of basic medical sciences2019

Irisin protects the substantia nigra dopaminergic neurons in the rat model of Parkinson's disease.

Sam Zarbakhsh, Manouchehr Safari, Mohammad Reza Aldaghi, Hamid Reza Sameni, Laya Ghahari, Younes Khaleghi Lagmouj, Khojasteh Rahimi Jaberi, Houman Parsaie

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Irisin/PGC-1α/FNDC5 pathway in Parkinson's disease: truth under the throes.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  16. Article
  17. FNDC5/Irisin in dementia and cognitive impairment: update and novel perspective.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sam ZarbakhshResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Manouchehr SafariResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Mohammad Reza AldaghiResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Hamid Reza SameniResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Laya GhahariDepartment of Anatomy, AJA University of Medical Sciences, Tehran, Iran.
Younes Khaleghi LagmoujResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Khojasteh Rahimi JaberiResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Houman ParsaieResearch Center of Nervous System Stem Cells, Department of Anatomy, Semnan University of Medical Sciences, Semnan , Iran.
Aja University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesExercise ameliorates the quality of life and reduces the risk of neurological derangements such as Alzheimer's (AD) and Parkinson's disease (PD). Irisin is a product of the physical activity and is a circulating hormone that regulates the energy metabolism in the body. In the nervous system, Irisin influences neurogenesis and neural differentiation in mice. We previously demonstrated that co-treatment of bone marrow stem cells (BMSCs) with a neurotrophic factor reduce Parkinson's symptoms. Our goal in this project was to evaluate whether Irisin with BMSCs can protect the dopaminergic (DA) neurons in PD. MATERIALS AND

methods35 adult male Wistar rat weighing (200-250 g) were chosen. They were separated into five experimental groups (n=7). To create a Parkinson's model, intranasal (IN) administration of the MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) was used. The BMSCs (2×106) and Irisin (50 nm/ml) was used for 7 days for treatment after creation of the PD model. After completion of the tests (4 weeks), their brains were used for the TUNEL and immunohistochemical (IHC) assays.

resultsOne of the important results of this study was that the Irisin induce BMSCs transport into the injured area of the brain. Co-treatment of the Irisin with BMSCs increased tyrosine hydroxylase-positive neurons (TH+) in substantia nigra (SN) and striatum of the PD mice brain. In this group, the number of TUNEL-positive cells significantly decreased. Behavioral symptoms were better in the combination group and Irisin simultaneously.

conclusionCo- treatment of Irisin with BMSCs protects the DA neurons from degeneration and apoptotic process after MPTP injection.

Indexed as

IrisinMesenchymal stem cellsParkinson’s diseaseSubstantia nigraTunel

Identifiers

PMID32373292
PMCPMC7196356
OpenAlexW2945379251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.